Visumax Femtosecond Laser
Carl Zeiss Meditec, Inc. · Decision date May 20, 2026
What did the FDA decide?
FDA records P150040/S025 as a supplement to PMA P150040, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 20, 2026.
FDA approval order statement
a change to an in-process quality control parameter for creep testing
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- May 20, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P150040/S025
- Regulatory pathway
- PMA supplement
- Applicant
- Carl Zeiss Meditec, Inc.
- Product code
- OTL
- Decision code
- OK30
- Decision date
- May 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Femtosecond laser system for refractive correction.
- Applicant
- Carl Zeiss Meditec, Inc.
- Product code
- OTL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P150040/S021 · Related supplement
Visumax; VISUMAX 800
P150040/S023 · Related supplement
VISUMAX 800 Femtosecond Laser
P150040/S020 · Related supplement
VisuMax; VISUMAX 800
P150040/S025 received
Application receipt date recorded by FDA.
P150040/S025 · FDA decision
30-Day Notice
P150040/S024 · Related supplement
VISUMAX 800 Femtosecond Laser
Timeline entries are records held by MedtechLedger for P150040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Visumax; VISUMAX 800P150040/S021 | Carl Zeiss Meditec, Inc. | PMA supplement | Aug 21, 2025 | FDA |
VISUMAX 800 Femtosecond LaserP150040/S023 | Carl Zeiss Meditec, Inc. | PMA supplement | Oct 16, 2025 | FDA |
VisuMax; VISUMAX 800P150040/S020 | Carl Zeiss Meditec, Inc. | PMA supplement | Dec 18, 2025 | FDA |
VISUMAX 800 Femtosecond LaserP150040/S024 | Carl Zeiss Meditec, Inc. | PMA supplement | May 26, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Carl Zeiss Meditec, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5160 Hacienda Dr., Dublin, CA, 94568
Sources and methodology
- Original FDA record: P150040/S025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


